Scientists at the Scripps Research Institute (TSRI) have described a new technique for adding glycans to cells and screening interactions between glycans and proteins. Their study (“Cell-Based Glycan Arrays for Probing Glycan–Glycan Binding Protein Interactions”), published in Nature Communications, may expand research on the roles of glycans in human diseases, including cancers, according to the team.
“Glycan microarrays provide a high-throughput means of profiling the interactions of glycan-binding proteins with their ligands. However, the construction of current glycan microarray platforms is time consuming and expensive. Here, we report a fast and cost-effective method for the assembly of cell-based glycan arrays to probe glycan–glycan-binding protein interactions directly on the cell surface. Chinese hamster ovary cell mutants with a narrow and relatively homogeneous repertoire of glycoforms serve as the foundation platforms to develop these arrays,” write the investigators.
“Using recombinant glycosyltransferases, sialic acid, fucose, and analogs thereof are installed on cell-surface glycans to form cell-based arrays displaying diverse glycan epitopes that can be probed with glycan-binding proteins by flow cytometry. Using this platform, high-affinity glycan ligands are discovered for Siglec-15—a sialic acid-binding lectin involved in osteoclast differentiation. Incubating human osteoprogenitor cells with cells displaying a high-affinity Siglec-15 ligand impairs osteoclast differentiation, demonstrating the utility of this cell-based glycan array technology.”
“Scientists have been trying to make glycan arrays that every scientist interested in glycans can access in their own labs for years,” says Peng Wu, Ph.D., a TSRI associate professor and senior author of the study. “We've not only done it, but we've done it in a way that's very easy.”
The patterns of glycans and glycan-binding proteins on a cell's membrane can differentiate cancer cells from healthy cells, control cells' roles in development, and contribute to diverse interactions between adult cells, explains Dr. Wu. Genetic diseases that affect the ability of cells to properly create glycans can shorten lifespan and lead to musculoskeletal problems.
But studying glycans has been problematic. While scientists know how to synthesize diverse proteins and DNA molecules in the lab, creating glycans on demand has been chemically challenging.
To study which proteins in a cell interact with glycan molecules, researchers have typically turned to glycan-binding arrays, in which dozens or hundreds of glycans are attached to a glass slide. Researchers then expose the slide to cells or proteins of interest and observe whether the cells or proteins stick to the glycans on the slide. But making these arrays is time-consuming and expensive.
“In the past, if you wanted to make an array with 100 sugars, then you had to chemically synthesize 100 sugars individually, which can be difficult,” says Dr. Wu. “Only specialized carbohydrate chemists can make them in certain labs.”
Dr. Wu and his colleagues instead decided to harness the power of the enzymes that cells use naturally to produce glycans. These enzymes work in a stepwise fashion to create branching glycans—one small piece of a sugar is made by one specialized enzyme, then another enzyme creates the next branch in the chain, and so on. The researchers found that even structurally related unnatural sugars can be added in this way.
Dr. Wu's team began with mutated rodent ovary cells that had a very narrow repertoire of glycans on their surface. This was a simpler system than using human cells with many types of glycans. The researchers then exposed the cells to different sets of glycan-creating enzymes to control the addition of carbohydrate branches to the glycans on each cell.
With this method, they created cell arrays, each studded with different glycans, including unnatural ones.
“The only limitations are the enzymes that we have available and the fact that you have to start with cells that already have simple glycosylation,” says Dr. Wu. “But we were able to create all the glycans we wanted.”
To test the utility of the new cell array, the scientists screened an array of cells, each displaying different glycans, to determine which ones bound to Siglec-15, a known glycan-binding protein that plays a role in bone development and remodeling. Siglec-15 is considered a potential target for drugs treating postmenopausal osteoporosis, so understanding how it interacts with carbohydrates is critical. The team identified three structures with strong binding to Siglec-15.
The researchers then incubated human osteoprogenitor cells with mutated rodent ovary cells displaying one of the three structures during differentiation. The team found that this process suppressed the formation of osteoclasts, a Siglec-15-expressing bone cell that absorbs bone tissue during growth and healing. This finding reinforces the idea that Siglec-15 is a good target for osteoporosis treatments, and that the new glycan-screening strategy can point researchers to promising new drugs.
“We don't know if this will be used in the broad community—it depends on the availability of enzymes and cells,” says Dr. Wu. “But if a whole bunch of cells with simple and homogeneous glycans can be made available, that would be huge for the field.”